18:27 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Adverum reviewing capsid after discontinuing AAT gene therapy

Adverum Biotechnologies Inc. (NASDAQ:ADVM) will discontinue development of gene therapy ADVM-043 to treat α-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency. The company said that although ADVM-043 was well tolerated among six patients in the open-label, U.S....
14:45 , Nov 2, 2018 |  BC Extra  |  Clinical News

Adverum reviewing capsid after discontinuing AAT gene therapy

Adverum Biotechnologies Inc. (NASDAQ:ADVM) sank $1.21 (27%) to $3.34 on Friday after it said it will discontinue development of gene therapy ADVM-043 to treat α-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency. The company said late Thursday...
07:00 , Aug 9, 2016 |  BC Extra  |  Company News

Editas, Adverum partner to treat retinal diseases

Editas Medicine Inc. (NASDAQ:EDIT) and Adverum Biotechnologies Inc. (NASDAQ:ADVM) will collaborate to develop gene editing-based treatments for up to five inherited retinal diseases. The deal combines Adverum's next-generation adeno-associated viral (AAV) vectors with Editas' genome...
07:00 , May 23, 2016 |  BC Week In Review  |  Company News

Annapurna Therapeutics, Avalanche Biotechnologies deal

Avalanche completed its acquisition of Annapurna for about $105.6 million in a stock deal and renamed the combined company as Adverum Biotechnologies Inc. (see BioCentury, Feb. 8). Annapurna Therapeutics S.A.S. , Paris, France   Avalanche...
08:00 , Feb 8, 2016 |  BC Week In Review  |  Company News

Annapurna Therapeutics, Avalanche Biotechnologies deal

Avalanche will acquire Annapurna, gaining four preclinical adeno-associated virus (AAV) gene therapy programs. The programs include ANN-001 , an AAV vector delivering alpha-1 antitrypsin ( AAT ; A1AT ; SERPINA1 ) to treat AAT deficiency;...
02:48 , Feb 2, 2016 |  BC Extra  |  Company News

Avalanche acquires Annapurna

Avalanche Biotechnologies Inc. (NASDAQ:AAVL) will acquire Annapurna Therapeutics S.A.S. (Paris, France), gaining four preclinical gene therapy programs outside of ophthalmology. Annapurna shareholders will receive 17.6 million new Avalanche shares, worth about $105.6 million based on...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Company News

Weill Cornell Medical College, Annapurna Therapeutics deal

Weill granted Annapurna an exclusive license to three preclinical gene therapy programs for alpha-1 antitrypsin deficiency (AATD), hereditary angioedema (HAE) and severe allergies. Annapurna expects to start clinical testing of the programs in 18-24 months....
02:08 , Jan 6, 2016 |  BC Extra  |  Company News

Annapurna gains Weill-Cornell gene therapy assets

Annapurna Therapeutics (Paris, France) received an exclusive license from Weill Cornell Medical College to three preclinical-stage gene therapy programs for alpha-1 antitrypsin deficiency (AATD), hereditary angioedema (HAE) and severe allergies. The company, formerly named AAVLife...
07:00 , Jul 23, 2015 |  BC Innovations  |  Tools & Techniques

Gene therapy's coming of age

After more than 20 years of trial and error in gene therapy, the field is taking off with one product approved in Europe, several poised to enter the market in the U.S., a surge of...
08:00 , Feb 26, 2015 |  BC Innovations  |  Finance

Europe waking to the American dream

While Europe didn't see the spike in seed and series A financing that the U.S. biotech sector enjoyed in 2014, there are signs the region is beginning to capitalize on the strength of its academic...